Patented At Home Vision Testing Platform For Sale

Patented At-Home Vision Testing Platform San Jose, CA (Santa Clara County) Asking Price: Best Possible Offer Cash Flow: $28,490 Gross Revenue: $359,491 EBITDA: N/A FF&E: $100,000 Inventory: $655,000 Established: 2015 Employees: 7 Business Description: A rare opportunity to acquire the only fully built, clinically validated, FDA-registered at-home vision diagnostics platform shipping at scale. A 29-patent portfolio pairs with proprietary, MIT-licensed optical technology and a HIPAA-compliant telehealth network that delivers prescriptions across 40 U.S. states. Over 50,000 devices sold in 150+ countries over eight years of commercial operation — with zero product defects, zero MDRs, and zero product litigation throughout the entire history of the business. This is a commercialization investment, not a technology-development bet. More than $31 million has been invested to date for software and product development, inventory, and marketplace testing. WHY THIS IS EXCEPTIONAL ◉ Patented, smartphone-based vision diagnostics platform – test vision, measure refractive error, and obtain prescriptions remotely. ◉ Exclusive license to MIT inverse Shack-Hartmann refraction technology — the foundational science behind the platform. ◉ 29-patent portfolio (granted plus pending) covering smartphone diagnostics, optical measurement, automated vision tracking, and PD measurement. ◉ Seven FDA-registered medical devices and apps – refraction, visual acuity, contrast, color, Amsler, PD, and reading-numbers measurement. ◉ Full compliance stack: ISO 13485, ISO 9001, HIPAA, and a state medical device manufacturer license – a five-cert posture few digital-health platforms hold at once. ◉ Four registered clinical trials on ClinicalTrials.gov, including a non-inferiority study versus phoropter and autorefractor, plus multiple CES Innovation Awards and a 2020 Frost Radar award. ◉ Blue-chip B2B relationships — including a national pharmacy chain, a major health system, and a leading online eyewear retailer (founded by the company’s own co-founder). ◉ Proprietary longitudinal vision dataset across the deployed fleet – a substrate for AI-driven diagnostics, predictive care, and population-health analytics. ◉ Substantial finished-goods inventory plus contract-manufacturing relationships in place – supporting immediate scale with no manufacturing lead-time exposure. ◉ Clean financial posture: no debt, no loans, capital on hand, and a prior $25M strategic asset transaction demonstrating realized value in the IP. THE UPSIDE FOR STRATEGIC AQUIRER The platform is fully developed but deliberately under-commercialized – the remaining work is commercial scale, not technology build-out. Multiple paths to value creation: ◉ Scale direct-to-consumer adoption and conversion from testing to prescription to eyewear purchase. ◉ Build recurring revenue — vision-tracking subscriptions and Rx renewal services across the installed base. ◉ Expand B2B partnerships with optical retailers, clinics, telehealth platforms, and pharmacies. ◉ Monetize the proprietary dataset for AI diagnostics and predictive care. ◉ Expand into global and underserved markets where low-cost remote diagnostics travel well. NDA is required {SUBMIT BELOW} to secure the comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.